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genes (genetic heterogeneity). Mapping of the DHSt
and FP genes7,9 now allows us to address this prob-
lem by means of a linkage analysis. Genomic DNA
was obtained from each member of a pedigree
described elsewhere.9 Linkage analysis was per-
formed using 8 microsatellite markers (D16S511,
D16S3037, D16S520, D16S498, D16S3074,
D16S3026, D16S3121) from the chromosome 16
region where we have previously mapped both DHSt
and FP.7,8 The analysis reveals the absence of segre-
gation between the above mentioned markers and
the disease locus, as shown in Table 1. These results
indicate that these pseudohyperkalemic variants are
genetically heterogenous with a locus on 16q23 and
at least one additional locus, which remains to be
mapped. Work is in progress to map this new locus
and to understand the molecular basis10 underlying
this interesting form of stomatocytosis.
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The hereditary stomatocytoses (HSt) are a group
of rare, dominantly inherited hemolytic anemias
showing abnormal membrane permeability to the
univalent cations Na+ and K+. They are clinically and
pathophysiologically heterogenoeous. The group
includes  overhydrated HSt (OHSt), the original condi-
tion,1 dehydrated HSt (DHSt; hereditary xerocyto-
sis),2 the commonest form, now seen to be het-
erogenous,3,4 cryohydrocytosis,5 in which red cells
lyse markedly if stored at low temperatures, and
familial pseudohyperkalemia,6a non-hemolytic con-
dition in which the red cells show a net loss of K+ at
room temperature, manifesting as high plasma [K]
levels. The gene responsible for both DHSt and famil-
ial pseudohyperkalemia (FP) has been mapped to
16q23-qter.7,8 In spite of the variability of the pre-
sentation, all kindreds that we have mapped so far
show linkage to this locus.
Recently, Coles9 described an unusual form of
hereditary stomacytosis associated with very marked
pseudohyperkalemia. Temperature studies of the
passive leak ﬂuxes of K showed the same shallow slope
abnormality as seen in classical familial pseudohy-
perkalemia, but in addition, the ﬂuxes at 37°C were
significantly increased; and frank hemolysis, with
abnormal intracellular [Na] and [K] levels, was pre-
sent. Superﬁcial examination might imply that this
new condition is simply a more severe, frankly
hemolytic, version of ‘classical’ FP.
We have sought to establish whether the clinical
and biochemical heterogeneity of these conditions
stems from different mutations of the same gene
(allelic heterogeneity) or from mutations in different
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Table 1. Pairwise LOD scores between FP family and chro-
mosome 16 markers.
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D16S3037 - Ï -4.18 -2.16 -1.33 -0.58 -0.22 -0.05 -9.05 0.5
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D16S498 - Ï -4.26 -2.23 -1.40 -0.63 -0.27 -0.07 -4.44 0.53
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D16S413 - Ï -2.51 -1.18 -0.67 -0.25 -0.08 -0.01 -2.48 0.50
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In vitro drug-induced cytotoxicity predicts
clinical response to high-dose chlorambucil in
B-cell chronic lymphocytic leukemia
Sir,
Chlorambucil (CLB) can be considered the golden
standard of  front-line therapy for B-cell chronic lym-
phocytic leukemia (CLL).1 In spite of its long use, the
best schedule of CLB administration has not yet been
established. We have demonstrated the clinical
advantage of a high-dose continuous CLB schedule
(HD-CLB) over standard-dose intermittent CLB2and
the CHOP regimen.3 In addition, according to the
results of an interim analysis of the ongoing ran-
domized EORTC study, the efficacy of HD-CLB is
apparently not inferior to that of ﬂudarabine,4 thus
conﬁrming that we can now two efﬁcient therapeu-
tic options for front-line therapy of CLL.
We recenlty demonstrated that in vitro drug-sensi-
tivity to fludarabine is associated with in vivo
response.5This study was aimed at analyzing whether
the ability of CLB to induce in vitrocytotoxicity in fresh
isolated CLL cells might be related to the in vivo out-
come of patients treated with the HD-CLB schedule. 
Twenty-nine previously untreated CLL patients
entered this study. Clinico-hematologic data, CLB-
LD50 value and the in vivo clinical response to high-
dose CLB are reported in Table 1. Criteria for treat-
ment, high-dose CLB schedules and deﬁnitions of
response have been described elsewhere.2-4The drug-
induced effect on cell viability was assessed by a non-
clonogenic 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium (MTT) assay that has been repeatedly
used to test in vitro chemosensitivity of CLL cells to
CLB.7, 8 Cells were continuously exposed to the drug
for 4 days. Median CLB-LD50value was 25, 16 and 58
µg/mL in patients obtaining complete (CR), partial
(PR) and no response (NR), respectively (p=ns for
Kruskall Wallis test).
Rai and Binet stage, TTM score and age (Table 2)
did not affect the response rate (CR+PR). However, a
signiﬁcantly higher number of responses was observed
in males and in those patients showing in vitro CLB-
LD50 values below 26 µg/mL. In spite of the relatively
small number of cases, the relevance of this parame-
ter was conﬁrmed by multivariate analysis. The short
median follow-up time hampers a statistically reliable
analysis of survival. However, since response to thera-
py is a parameter well known to be associated with
longer survival,9 it is reasonable to expect that in vitro
resistance to CLB coulde be an early indicator of an
overall unfavorable outcome of patients treated with
this alkylating agent. 
In conclusion, in our experience the in vitro MTT
assay is a useful tool for predicting in vivo treatment
failure to HD-CLB in CLL. Thus, from the results
obtained in cytotoxicity tests induced by different
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Table 1. Main clinico-hematological data, CLB-LD50 value
and clinical response to high-dose CLB.
Sex, male/female  13/16











TTM score, mean ± sem 12.4 ± 0.72
≤ 95
> 9 24
CLB-LD50 µg/mL (mean ± sem) 47.1 ± 7.2




Table 2. Univariate and logistic multivariate regression
analysis of prognostic variables for clinical response to HD-
CLB.
Variable CR+PR NR Uni-* Multi-°
variate
pp
Rai stage (0-II v III-IV) 11 v 11 3 v 4 1.0 ---
Binet stage (A-B v C) 15 v 7 3 v 4 0.3 ---
TTM score (≤ 11.4 v > 11.4) 11 v 11 5 v 2 0.4 ---
Age, years (≤ 74 v > 74) 11 v 11 4 v 3 1.0 ---
Sex (male v female) 13 v 9 0 v 7 0.008 ns
CLB-LD50, µg/mL (≤ 26 v > 26) 14 v 8 1 v 6 0.035 0.05
*Fisher exact test (2-tail); °Logistic regression analysis.